Lucentis first VEGF inhibitor approved for DME in Japan

Save

The new approval for Lucentis in the additional indication was supported by results from the Phase III REVEAL study in around 400 patients across six Asian countries, including Japan. This showed a significant increase in mean visual acuity at 12 months…